Serum cholesterol distribution and coronary heart disease risk: Observations and predictions among middle-aged population in eastern Finland

Circulation

Volumn 97, Issue 11, 1998, Pages 1087-1094

  Jousilahti, Pekka ^a   Vartiainen, Erkki ^a   Pekkanen, Juha ^a   Tuomilehto, Jaakko ^a   Sundvall, Jouko ^a   Puska, Pekka ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Cholesterol; Coronary disease; Mortality; Prevention

Indexed keywords

CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; FAT INTAKE; FEMALE; FINLAND; HUMAN; ISCHEMIC HEART DISEASE; MALE; MORTALITY; NORMAL HUMAN; PRIORITY JOURNAL; RISK FACTOR;

EID: 0032562255     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.11.1087     Document Type: Review

References (34)

1. Thom TJ, Epstein FH, Feldman JJ, Leaverton PE, Wolz M. Total Mortality and Mortality From Heart Disease, Cancer and Stroke From 1950 to 1987 in 27 Countries. Washington, DC: US Dept of Health and Human Services; 1992. NIH publication No. 92-3088.
2. Interhealth Steering Committee. Demonstration projects for the integrated prevention and control of noncommunicabie diseases (Interhealth programme): epidemiological background and rationale. World Health Stat Q. 1991;44:48-54.
3. Murray CJL, Lopez AD. Evidence-based health policy lessons from the global burden of disease study. Science. 1996;274:740-743.
4. Keys A. Coronary Heart Disease in Seven Countries. New York, NY: American Heart Association; 1970. Monograph No. 29.
5. Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project. J Chronic Dis. 1978;31:201-306.
6. Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Arch Intern Med. 1992;152:56-64.
7. Lipid Research Clinic Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984; 251:365-374.
8. Keys A, Anderson JT, Grande F. Serum cholesterol response to changes in the diet, IV: particular saturated fatty acids in the diet. Metabolism. 1965; 14:776-787.
9. Stamler J. Research related to risk factors. Circulation. 1979;60:1575-1587.
10. Puska P, Tuomilehto J, Nissinen A, Vartiainen E. The North Karelia Project: 20-Year Results and Experiences. Helsinki, Finland: National Public Health Institute, KTL; 1995.
11. Nissinen A, Tuomilehto J, Puska P. From pilot project to national implementation: experiences from the North Karelia Project. Scand J Prim Health Care Suppl. 1988;1:49-56.
12. Vartiainen E, Puska P, Jousilahti P, Korhonen HJ, Tuomilehto J. Twenty year trends in coronary risk factors in North Karelia and in other areas in Finland. Int J Epidemiol. 1994;23:495-503.
13. WHO MONICA Project Principal Investigators. The World Health Organization MONICA Project (monitoring trends and determinant in cardiovascular disease): a major international collaboration. J Clin Epidemiol. 1988;41:105-114.
14. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ. 1994;308:363-366.
15. SAS/STAT User's Guide, Version 6. 4th ed. Cary, NC: SAS Institute Inc; 1990;vol 1-2.
16. Committee of Principal Investigators. World Health Organization co-operative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: the final mortality follow-up. Lancet. 1984;2:600-604.
17. Oliver MF. Prevention of coronary heart disease: propaganda, promises, problems, and prospects. Circulation. 1986;73:1-9.
18. McCormick J, Skrabanek P. Coronary disease is not preventable by population interventions. Lancet. 1988;2:839-841.
19. Low MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994;308:373-379.
20. Pietinen P, Vartiainen E, Seppänen R, Aro A, Puska P. Changes in diet in Finland from 1972 to 1992: impact on coronary heart disease risk. Prev Med. 1996;25:243-250.
21. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Twenty-year dynamics of serum cholesterol levels in the middle-aged population in eastern Finland. Ann Intern Med. 1996;125:713-722.
22. Pekkanen J, Uutela A, Valkonen T, Vartiainen E, Tuomilehto J, Puska P. Coronary risk factor levels: differences between educational groups in 1972 to 87 in eastern Finland. J Epidemiol Community Health. 1995;49:144-149.
23. Vartiainen E, Puska P, Pekkanen J, Tuomilehto J, Jousilahti P. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ. 1994;309:23-27.
24. Jousilahti P, Vartiainen E, Tuomilehto J, Pekkanen J, Puska P. Effect of risk factors and changes in risk factors oil coronary mortality in three cohorts of middle-aged people in eastern Finland. Am J Epidemiol. 1995;141:50-60.
25. WHO MONICA Project. Geographical variation in the major risk factors of coronary heart disease in men and women aged 35-64. World Health Stat Q. 1988;41:115-140.
26. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
27. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
28. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997;336:332-336.
29. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. (The Scandinavian Simvastatin Survival Study [4S] Group). Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care. 1997;20:614-620.
30. Pyörälä K. CHD prevention in clinical practice. Lancet. 1996;348:s26-s28.
31. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med. 1995;333:1301-1307.
32. Fey R, Pearson N. Statins and coronary heart disease. Lancet. 1996;347: 1389-1390.
33. WHO MONICA Project (prepared by Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arvelier D, Rajakangas A-M, Pajak A). Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations irom 21 countries in four continents. Circulation. 1994;90:583-612.
34. Miettinen T, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med. 1996;333:1308-1312.